8-KOther Events

JOHNSON & JOHNSON 8-K Report (Oct 22, 2001)

Filed October 22, 2001For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on October 21, 2001, to report on its sales and earnings for the period ended September 30, 2001. This filing serves as a notification to investors about the company's financial performance during the third quarter of 2001. While the 8-K itself doesn't contain the detailed financial statements, it directs investors to an attached press release which presumably provides the specific sales figures and earnings per share for the period. Investors should review the referenced press release to understand the key financial metrics, including revenue growth, profitability, and any segment-specific performance. This information is crucial for assessing J&J's operational success, its ability to meet market expectations, and its overall financial health during this reporting period. Understanding these results provides insight into the company's ongoing strategy and its position within the healthcare industry.

Key Highlights

  • 1Johnson & Johnson (JNJ) filed an 8-K on October 21, 2001.
  • 2The filing pertains to the company's sales and earnings for the period ending September 30, 2001.
  • 3The earliest event reported is dated October 16, 2001.
  • 4The 8-K includes a press release (Exhibit 99.15) dated October 16, 2001, detailing the quarterly results.
  • 5This report is a key disclosure for investors to track the company's financial performance.
  • 6Investors are directed to the attached press release for specific sales and earnings data.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and report Johnson & Johnson's sales and earnings for the third quarter of 2001, which ended on September 30, 2001.

The 8-K filing itself does not contain the detailed financial results. Instead, it refers investors to an attached press release dated October 16, 2001 (Exhibit 99.15), which is expected to contain the specific sales and earnings figures.

The reported sales and earnings cover the period ended September 30, 2001, which corresponds to the company's third quarter of that fiscal year.

Investors should look for key financial metrics such as total sales, revenue growth, net earnings, earnings per share (EPS), and potentially segment-specific performance (e.g., Pharmaceuticals, Medical Devices, Consumer Health). This information helps in assessing the company's financial health and operational trends.